Pleural Fluid MALDI Study

• Start Date: 11 Jan 2005
• Research Drive Directory: /Massion/050111
• Data Type: MassSpec
• Notes: re-analyse based on re-binned data sets, the original analysis are under /Massion/040702
• Status: 100%

Output

• Leave One Out : ./deliverable
• graphs: ./all graphs
• survival : ./survival/sas data

Analysis Requests

• A. find discriminat peptide/protein for the following groups
  • Q1: all tumors vs. non-tumor (52/49) in training set and all tumor vs. non-tumor (42/40) in testing set
  • Q2: lung cancer vs. non-tumor (30/49) in training set and lung cancer cyto+ vs. non-tumor(25/40) in the testing set
  • Q3: lung cancer vs. other tumors_breast tumors (30/22) in training set and lung cancer cyto+ vs. other tumors_breast(25/17) in the testing set
  • Q4
    • A. Apply discriminants found in Q1 training (all tumor 52 versus non-tumor 49) to the cyto negative lung group who have lung cancer ( N:13) as a test set.
    • B. Apply discriminants found in Q2 training (lung cancer 30 vs non-tumor 49) to the cyto negative lung group who have lung cancer ( N:13) as a test set.

• B. Survival Analysis : Survival-predictors should be tested in a training and testing set strategy in these groups: A Q1, A Q2, A Q4A, and AQ4B. The survival should be calculated as the difference between date of diagnosis of pleural effusion and Date of death or LDKA.

Change Log:

Contact Info:

• Primary Study Contact Person: Noel Wardwell (615.322.3412)

Analyst

• JoanZhang